|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM113152221 |
| 003 |
DE-627 |
| 005 |
20231222163254.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0378.xml
|
| 035 |
|
|
|a (DE-627)NLM113152221
|
| 035 |
|
|
|a (NLM)11411097
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Ohuchi, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.07.2001
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Eighteen patients with locally invasive bladder cancer were treated with 1 or 2 cycles of neoadjuvant chemotherapy consisting of methotrexate, epirubicin and cisplatin (MEC). All patients underwent radical cystectomy and pelvic lymph node dissection. Down-staging was observed in twelve (complete pathological response in 3 and partial pathological response in 9) patients (response rate were 67%). Four of the 18 patients died of disease and all of them had not achieved down-staging. Multivariate analysis revealed nodal status to be the only independent predictor. With regard to side effects, gastrointestinal symptoms and myelo-suppression were observed in almost all patients. Thrombocytopenia was observed in 13 patients (72%) including 7 patients who showed symptoms over grade 3. Gastro-intestinal symptoms and leukocytopenia disappeared with granisetron and granulocyte colony stimulating factor. There were no treatment-related deaths in this study. These results indicate that MEC therapy was safely performed and showed a high response rate in patients with locally invasive bladder cancer
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Epirubicin
|2 NLM
|
| 650 |
|
7 |
|a 3Z8479ZZ5X
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Noguchi, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takase, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kawakami, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ikeda, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saito, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yao, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Masuda, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kubota, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hosaka, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 47(2001), 4 vom: 24. Apr., Seite 241-6
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2001
|g number:4
|g day:24
|g month:04
|g pages:241-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2001
|e 4
|b 24
|c 04
|h 241-6
|